Skip to Content
Merck

Inhibition of monoacylglycerol lipase reduces nicotine withdrawal.

British journal of pharmacology (2014-09-27)
P P Muldoon, J Chen, J L Harenza, R A Abdullah, L J Sim-Selley, B F Cravatt, M F Miles, X Chen, A H Lichtman, M I Damaj
ABSTRACT

Abrupt discontinuation of nicotine, the main psychoactive component in tobacco, induces a withdrawal syndrome in nicotine-dependent animals, consisting of somatic and affective signs, avoidance of which contributes to drug maintenance. While blockade of fatty acid amide hydrolase, the primary catabolic enzyme of the endocannabinoid arachidonoylethanolamine (anandamide), exacerbates withdrawal responses in nicotine-dependent mice, the role of monoacylglycerol lipase (MAGL), the main hydrolytic enzyme of a second endocannabinoid 2-arachidonylglycerol (2-AG), in nicotine withdrawal remains unexplored. To evaluate the role of MAGL enzyme inhibition in nicotine withdrawal, we initially performed a genetic correlation approach using the BXD recombinant inbred mouse panel. We then assessed nicotine withdrawal intensity in the mouse after treatment with the selective MAGL inhibitor, JZL184, and after genetic deletion of the enzyme. Lastly, we assessed the association between genotypes and smoking withdrawal phenotypes in two human data sets. BXD mice displayed significant positive correlations between basal MAGL mRNA expression and nicotine withdrawal responses, consistent with the idea that increased 2-AG brain levels may attenuate withdrawal responses. Strikingly, the MAGL inhibitor, JZL184, dose-dependently reduced somatic and aversive withdrawal signs, which was blocked by rimonabant, indicating a CB1 receptor-dependent mechanism. MAGL-knockout mice also showed attenuated nicotine withdrawal. Lastly, genetic analyses in humans revealed associations of the MAGL gene with smoking withdrawal in humans. Overall, our findings suggest that MAGL inhibition maybe a promising target for treatment of nicotine dependence.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Mecamylamine hydrochloride
Nicotine for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Ethanol solution, certified reference material, 2000 μg/mL in methanol
Supelco
Dehydrated Alcohol, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Dehydrated Alcohol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ethanol, for residue analysis
Sigma-Aldrich
Ethanol, BioUltra, for molecular biology, ≥99.8%, (absolute alcohol, without additive, A15 o1)
Supelco
Adenosine, Pharmaceutical Secondary Standard; Certified Reference Material
Adenosine, European Pharmacopoeia (EP) Reference Standard
Supelco
Mycophenolic acid, analytical standard
Sigma-Aldrich
Mycophenolic acid, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Mycophenolic acid, ≥98%
Sigma-Aldrich
Adenosine, ≥99%
Sigma-Aldrich
Adenosine, suitable for cell culture, BioReagent
Sigma-Aldrich
Ethanol, tested according to Ph. Eur.
Sigma-Aldrich
Adenosine
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, ACS reagent, ≥99.5%
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, meets USP testing specifications
Sigma-Aldrich
Ethanol, purum, absolute ethanol, denaturated with 4.8% isopropanol, A15 IPA1, ≥99.8% (based on denaturant-free substance)
Sigma-Aldrich
Ethanol, purum, fine spirit, denaturated with 4.8% methanol, F25 METHYL1, ~96% (based on denaturant-free substance)
Sigma-Aldrich
Ethanol, purum, absolute ethanol, denaturated with 2% 2-butanone, A15 MEK1, ≥99.8% (based on denaturant-free substance)
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, for molecular biology
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, for molecular biology